RxDoctor Payments Data

Roy Harris, DO

Internal Medicine · Bucyrus, OHNPI 1043218902

Payments from drug & device makers

$19,720in general payments, 2019–2025

Across 637 payments — averaging $30.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$10K
  • AbbVie$2K
  • AstraZeneca$1K
  • Lilly USA, LLC$927
  • Novo Nordisk$613
  • Boehringer Ingelheim$552
  • plus $4K from 42 others

What the payments were for

  • Consulting fees$8,28742%
  • Speaking & faculty fees$5503%
  • Travel & lodging$1,4087%
  • Food & beverage$9,42948%
  • Education$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,720 in reported general payments places this provider in the 95th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$108,775
Medicare patients
158
Services billed
1,156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban174$73,176
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$47,064
FarxigaDapagliflozin Propanediol43$30,248
TrulicityDulaglutide25$21,715
ErtapenemErtapenem Sodium43$18,683
JardianceEmpagliflozin32$14,675
XareltoRivaroxaban39$13,518
KerendiaFinerenone17$11,638
LinzessLinaclotide20$10,776
Celecoxib182$10,286
Synjardy XrEmpagliflozin/Metformin Hcl14$8,287
Sucralfate124$6,511
Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm26$6,302
Divalproex Sodium46$4,994
Olanzapine255$4,775

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$128$73,176174 claims
GSKTrelegy Ellipta$360$47,06454 claims
AstraZenecaFarxiga$1,246$30,24843 claims
Lilly USA, LLCTrulicity, Olanzapine$927$26,490280 claims
Boehringer IngelheimJardiance, Synjardy Xr$552$22,96246 claims
Johnson & JohnsonXarelto$273$13,51839 claims
BayerKerendia$10,450$11,63817 claims
AbbVieLinzess$1,672$10,77620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Bucyrus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →